title: Effects of bethanechol chloride and distigmine bromide on postvoiding residual volume in patients with underactive bladder.
abstract: OBJECTIVE
  The efficacy of cholinergic drugs for reduction of post-voiding residual volume (PVR) in patients with underactive bladder is still controversial. This study was performed to examine whether cholinergic drugs have such an effect on PVR.
  
  
  METHODS
  Patients with underactive bladder treated for more than two months with cholinergic drugs, which were later discontinued, were extracted retrospectively based on their charts. The changes in PVR, cholinesterase activity (ChE), renal function, and voiding function before and after discontinuation of cholinergic drugs were reviewed and analyzed.
  
  
  RESULTS
  Twenty-nine patients were included in this study. In multiple linear regression analysis, the discontinuation of distigmine bromide (DB) was indicated as a significant covariate for PVR increase and ChE increase, while bethanechol chloride (BC) was not a significant covariate. The increase in ChE was significantly correlated with both PVR and voided volume after discontinuation of cholinergic drugs.
  
  
  CONCLUSIONS
  DB could reduce PVR via a decrease in ChE. However, BC at doses up to 60 mg did not reduce PVR. DB may be recommended for the reduction of PVR in patients with underactive bladder.
authors.affiliation: Department of Integrative Cancer Therapy and Urology Kanazawa University Graduate School of Medical Science, Kanazawa, Japan - azuizu2003@yahoo.co.jp.
authors.forename: K
authors.initials: K
authors.lastname: Izumi
authors.forename: A
authors.initials: A
authors.lastname: Maolake
authors.forename: Y
authors.initials: Y
authors.lastname: Maeda
authors.forename: K
authors.initials: K
authors.lastname: Shigehara
authors.forename: M
authors.initials: M
authors.lastname: Namiki
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D018723:Bethanechol / Q000494:pharmacology / Q000627:therapeutic use*; D002800:Cholinesterase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018721:Muscarinic Agonists / Q000494:pharmacology / Q000627:therapeutic use*; D011726:Pyridinium Compounds / Q000494:pharmacology / Q000627:therapeutic use*; D012189:Retrospective Studies; D001743:Urinary Bladder / Q000187:drug effects*; D001745:Urinary Bladder Diseases / Q000188:drug therapy* / Q000503:physiopathology*
chemical_list: D002800:Cholinesterase Inhibitors; D018721:Muscarinic Agonists; D011726:Pyridinium Compounds; D018723:Bethanechol; C084645:distigmine